South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Imago BioSciences is raising $79,999,992.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Hugh Rienhoff played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Imago BioSciences

Our scientific efforts are aimed at developing drugs that improve the management of proliferative diseases of the bone marrow. Our clinical focus is on acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), polycythemia vera (PV), myelofibrosis (MF) and essential thrombocythemia (ET) û diseases sharing several features.

To learn more about Imago BioSciences, visit http://imagobio.com/

Contact:
Hugh Rienhoff, Chief Executive Officer
415-529-5055
hugh.rienhoff@imagobio.com
https://www.linkedin.com/in/rienhoff/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved